Cargando…
Durable SARS-CoV-2 B cell immunity after mild or severe disease
Multiple studies have shown loss of SARS-CoV-2 specific antibodies over time after infection, raising concern that humoral immunity against the virus is not durable. If immunity wanes quickly, millions of people may be at risk for reinfection after recovery from COVID-19. However, memory B cells (MB...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605583/ https://www.ncbi.nlm.nih.gov/pubmed/33140070 http://dx.doi.org/10.1101/2020.10.28.20220996 |
_version_ | 1783604331595956224 |
---|---|
author | Ogega, Clinton O. Skinner, Nicole E. Blair, Paul W. Park, Han-Sol Littlefield, Kirsten Ganesan, Abhinaya Ladiwala, Pranay Antar, Annukka AR Ray, Stuart C. Betenbaugh, Michael J. Pekosz, Andrew Klein, Sabra L. Manabe, Yukari C. Cox, Andrea L. Bailey, Justin R. |
author_facet | Ogega, Clinton O. Skinner, Nicole E. Blair, Paul W. Park, Han-Sol Littlefield, Kirsten Ganesan, Abhinaya Ladiwala, Pranay Antar, Annukka AR Ray, Stuart C. Betenbaugh, Michael J. Pekosz, Andrew Klein, Sabra L. Manabe, Yukari C. Cox, Andrea L. Bailey, Justin R. |
author_sort | Ogega, Clinton O. |
collection | PubMed |
description | Multiple studies have shown loss of SARS-CoV-2 specific antibodies over time after infection, raising concern that humoral immunity against the virus is not durable. If immunity wanes quickly, millions of people may be at risk for reinfection after recovery from COVID-19. However, memory B cells (MBC) could provide durable humoral immunity even if serum neutralizing antibody titers decline. We performed multi-dimensional flow cytometric analysis of S protein receptor binding domain (S-RBD)-specific MBC in cohorts of ambulatory COVID-19 patients with mild disease, and hospitalized patients with moderate to severe disease, at a median of 54 (39–104) days after onset of symptoms. We detected S-RBD-specific class-switched MBC in 13 out of 14 participants, including 4 of the 5 participants with lowest plasma levels of anti-S-RBD IgG and neutralizing antibodies. Resting MBC (rMBC) made up the largest proportion of S-RBD-specific class-switched MBC in both cohorts. FCRL5, a marker of functional memory when expressed on rMBC, was dramatically upregulated on S-RBD-specific rMBC. These data indicate that most SARS-CoV-2-infected individuals develop S-RBD-specific, class-switched MBC that phenotypically resemble germinal center-derived B cells induced by effective vaccination against other pathogens, providing evidence for durable B cell-mediated immunity against SARS-CoV-2 after recovery from mild or severe COVID-19 disease. |
format | Online Article Text |
id | pubmed-7605583 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Cold Spring Harbor Laboratory |
record_format | MEDLINE/PubMed |
spelling | pubmed-76055832020-11-03 Durable SARS-CoV-2 B cell immunity after mild or severe disease Ogega, Clinton O. Skinner, Nicole E. Blair, Paul W. Park, Han-Sol Littlefield, Kirsten Ganesan, Abhinaya Ladiwala, Pranay Antar, Annukka AR Ray, Stuart C. Betenbaugh, Michael J. Pekosz, Andrew Klein, Sabra L. Manabe, Yukari C. Cox, Andrea L. Bailey, Justin R. medRxiv Article Multiple studies have shown loss of SARS-CoV-2 specific antibodies over time after infection, raising concern that humoral immunity against the virus is not durable. If immunity wanes quickly, millions of people may be at risk for reinfection after recovery from COVID-19. However, memory B cells (MBC) could provide durable humoral immunity even if serum neutralizing antibody titers decline. We performed multi-dimensional flow cytometric analysis of S protein receptor binding domain (S-RBD)-specific MBC in cohorts of ambulatory COVID-19 patients with mild disease, and hospitalized patients with moderate to severe disease, at a median of 54 (39–104) days after onset of symptoms. We detected S-RBD-specific class-switched MBC in 13 out of 14 participants, including 4 of the 5 participants with lowest plasma levels of anti-S-RBD IgG and neutralizing antibodies. Resting MBC (rMBC) made up the largest proportion of S-RBD-specific class-switched MBC in both cohorts. FCRL5, a marker of functional memory when expressed on rMBC, was dramatically upregulated on S-RBD-specific rMBC. These data indicate that most SARS-CoV-2-infected individuals develop S-RBD-specific, class-switched MBC that phenotypically resemble germinal center-derived B cells induced by effective vaccination against other pathogens, providing evidence for durable B cell-mediated immunity against SARS-CoV-2 after recovery from mild or severe COVID-19 disease. Cold Spring Harbor Laboratory 2020-10-30 /pmc/articles/PMC7605583/ /pubmed/33140070 http://dx.doi.org/10.1101/2020.10.28.20220996 Text en https://creativecommons.org/licenses/by-nd/4.0/This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nd/4.0/) , which allows reusers to copy and distribute the material in any medium or format in unadapted form only, and only so long as attribution is given to the creator. The license allows for commercial use. |
spellingShingle | Article Ogega, Clinton O. Skinner, Nicole E. Blair, Paul W. Park, Han-Sol Littlefield, Kirsten Ganesan, Abhinaya Ladiwala, Pranay Antar, Annukka AR Ray, Stuart C. Betenbaugh, Michael J. Pekosz, Andrew Klein, Sabra L. Manabe, Yukari C. Cox, Andrea L. Bailey, Justin R. Durable SARS-CoV-2 B cell immunity after mild or severe disease |
title | Durable SARS-CoV-2 B cell immunity after mild or severe disease |
title_full | Durable SARS-CoV-2 B cell immunity after mild or severe disease |
title_fullStr | Durable SARS-CoV-2 B cell immunity after mild or severe disease |
title_full_unstemmed | Durable SARS-CoV-2 B cell immunity after mild or severe disease |
title_short | Durable SARS-CoV-2 B cell immunity after mild or severe disease |
title_sort | durable sars-cov-2 b cell immunity after mild or severe disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605583/ https://www.ncbi.nlm.nih.gov/pubmed/33140070 http://dx.doi.org/10.1101/2020.10.28.20220996 |
work_keys_str_mv | AT ogegaclintono durablesarscov2bcellimmunityaftermildorseveredisease AT skinnernicolee durablesarscov2bcellimmunityaftermildorseveredisease AT blairpaulw durablesarscov2bcellimmunityaftermildorseveredisease AT parkhansol durablesarscov2bcellimmunityaftermildorseveredisease AT littlefieldkirsten durablesarscov2bcellimmunityaftermildorseveredisease AT ganesanabhinaya durablesarscov2bcellimmunityaftermildorseveredisease AT ladiwalapranay durablesarscov2bcellimmunityaftermildorseveredisease AT antarannukkaar durablesarscov2bcellimmunityaftermildorseveredisease AT raystuartc durablesarscov2bcellimmunityaftermildorseveredisease AT betenbaughmichaelj durablesarscov2bcellimmunityaftermildorseveredisease AT pekoszandrew durablesarscov2bcellimmunityaftermildorseveredisease AT kleinsabral durablesarscov2bcellimmunityaftermildorseveredisease AT manabeyukaric durablesarscov2bcellimmunityaftermildorseveredisease AT coxandreal durablesarscov2bcellimmunityaftermildorseveredisease AT baileyjustinr durablesarscov2bcellimmunityaftermildorseveredisease |